257 related articles for article (PubMed ID: 22833464)
21. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
Simon A; Peoch M; Casassus P; Deconinck E; Colombat P; Desablens B; Tournilhac O; Eghbali H; Foussard C; Jaubert J; Vilque JP; Rossi JF; Lucas V; Delwail V; Thyss A; Maloisel F; Milpied N; le Gouill S; Lamy T; Gressin R
Br J Haematol; 2010 Oct; 151(2):159-66. PubMed ID: 20738307
[TBL] [Abstract][Full Text] [Related]
22. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
[TBL] [Abstract][Full Text] [Related]
23. A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.
Evens AM; Rosen ST; Helenowski I; Kline J; Larsen A; Colvin J; Winter JN; van Besien KM; Gordon LI; Smith SM
Br J Haematol; 2013 Oct; 163(1):55-61. PubMed ID: 23927371
[TBL] [Abstract][Full Text] [Related]
24. Ukraine Data on Prognostic Factors and Treatment Outcomes in Patients with Peripheral T-Cell Lymphomas.
Skrypets T; Novosad O; Pastushenko Y; Gorbach O; Kriachok I
Klin Onkol; 2019; 32(6):436-444. PubMed ID: 31842562
[TBL] [Abstract][Full Text] [Related]
25. Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis.
Kogure Y; Yoshimi A; Ueda K; Nannya Y; Ichikawa M; Nakamura F; Kurokawa M
Ann Hematol; 2015 Jun; 94(6):989-94. PubMed ID: 25687839
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
Movsas B; Langer CJ; Ross HJ; Wang L; Jotte RM; Feigenberg S; Xu F; Huang CH; Monberg MJ; Obasaju CK
J Thorac Oncol; 2010 May; 5(5):673-9. PubMed ID: 20354453
[TBL] [Abstract][Full Text] [Related]
27. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G
Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680
[TBL] [Abstract][Full Text] [Related]
28. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
[TBL] [Abstract][Full Text] [Related]
29. Phase II Trial Using Romidepsin after Gemcitabine, Dexamethasone, and Cisplatin Therapy in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Study Protocol.
Yamasaki S; Kada A; Nagai H; Yoshida I; Choi I; Saito AM; Iwasaki H
Acta Med Okayama; 2019 Oct; 73(5):469-474. PubMed ID: 31649375
[TBL] [Abstract][Full Text] [Related]
30. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.
Urakami S; Fujii Y; Yamamoto S; Yuasa T; Kitsukawa S; Sakura M; Yano A; Saito K; Masuda H; Yonese J; Fukui I
Urol Oncol; 2014 Jan; 32(1):35.e1-7. PubMed ID: 23562233
[TBL] [Abstract][Full Text] [Related]
32. Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma.
Puig N; Wang L; Seshadri T; al-Farsi K; Keating A; Crump M; Kuruvilla J
Leuk Lymphoma; 2013 Mar; 54(3):507-13. PubMed ID: 22897731
[TBL] [Abstract][Full Text] [Related]
33. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
Barr PM; Li H; Spier C; Mahadevan D; LeBlanc M; Ul Haq M; Huber BD; Flowers CR; Wagner-Johnston ND; Horwitz SM; Fisher RI; Cheson BD; Smith SM; Kahl BS; Bartlett NL; Friedberg JW
J Clin Oncol; 2015 Jul; 33(21):2399-404. PubMed ID: 26077240
[TBL] [Abstract][Full Text] [Related]
34. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.
Prochazka V; Faber E; Raida L; Vondrakova J; Kucerova L; Jarosova M; Indrak K; Papajik T
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):63-6. PubMed ID: 19365529
[TBL] [Abstract][Full Text] [Related]
35. All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma.
Cox MC; Banchi M; Pelliccia S; Di Napoli A; Marcheselli L; Patti C; Anticoli Borza P; Battistini R; Di Gregorio F; Orlandi P; Bocci G
Cancer Chemother Pharmacol; 2020 Dec; 86(6):841-846. PubMed ID: 33070248
[TBL] [Abstract][Full Text] [Related]
36. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.
Casulo C; Schöder H; Feeney J; Lim R; Maragulia J; Zelenetz AD; Horwitz S
Leuk Lymphoma; 2013 Oct; 54(10):2163-7. PubMed ID: 23369041
[TBL] [Abstract][Full Text] [Related]
37. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.
Kim SJ; Shin DY; Kim JS; Yoon DH; Lee WS; Lee H; Do YR; Kang HJ; Eom HS; Ko YH; Lee SH; Yoo HY; Hong M; Suh C; Kim WS
Ann Oncol; 2016 Apr; 27(4):712-8. PubMed ID: 26861608
[TBL] [Abstract][Full Text] [Related]
39. Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
Gleeson M; Peckitt C; Cunningham D; Gibb A; Hawkes EA; Back M; Yasar B; Foley K; Lee R; Dash J; Johnson H; O'Hara C; Wotherspoon A; Attygalle A; Menasce L; Shenjere P; Potter M; Ethell ME; Dearden C; Radford J; Chau I; Linton K
Leuk Lymphoma; 2018 Jul; 59(7):1586-1595. PubMed ID: 29119842
[TBL] [Abstract][Full Text] [Related]
40. Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.
Ludvigsen Al-Mashhadi A; Cederleuf H; Kuhr Jensen R; Holm Nielsen T; Bjerregård Pedersen M; Bech Mortensen T; Relander T; Jerkeman M; Ortved Gang A; Kristensen AL; Roost Clausen M; de Nully Brown P; Tang Severinsen M; Jakobsen LH; Ellin F; El-Galaly TC
Am J Hematol; 2023 Mar; 98(3):388-397. PubMed ID: 36588403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]